Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th ...

Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) ("Endo") today reported significant progress toward their proposed merger to create a global, scaled, diversified therapeutics leader.

We evaluated the effects of digital health technologies (DHTs) on women's health, empowerment, and gender equality, using the ...

“DA POPE!” blared the front of the Chicago Sun-Times on Friday, one of countless spins on the city’s unique accent, ...

As a dietitian who’s reviewed and tested dozens—if not hundreds—of products, I can confidently say supplements can make a ...